Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiuWeiLuoBi Granule for Diabetic Peripheral Neuropathy
NCT04457531Phase 1Unknown
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LiuWeiLuoBi Granule in diabetic peripheral neuropathy (DPN) (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoint: Mean maximal nerve conduction velocity at 12 weeks. Status: unknown.
02
Drugs
LiuWeiLuoBi Granule
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT04457531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457531.